Diabetes, Obesity and Metabolism
Displaying 1 - 6 of 6
İnam, M. G., İnam, O., Gucer, D., Park, J., Amellal, Y., Tezel, T. H., & Tezel, G. (2025). Obesity‐related early structural alterations in the retina detected by optical coherence tomography. Diabetes, Obesity and Metabolism. Portico. https://doi.org/10.1111/dom.16344
Publication Date
Columbia Affiliation
View
Santos‐Báez, L. S., Diaz‐Rizzolo, D. A., Borhan, R., Popp, C. J., Sordi‐Guth, A., DeBonis, D., Manoogian, E. N. C., Panda, S., Cheng, B., & Laferrère, B. (2025). Predictive models of post‐prandial glucose response in persons with prediabetes and early onset type 2 diabetes: A pilot study. Diabetes, Obesity and Metabolism. Portico. https://doi.org/10.1111/dom.16160
Publication Date
Columbia Affiliation
Geng, J., Ruan, X., Wu, X., Chen, X., Fu, T., Gill, D., Burgess, S., Chen, J., Ludvigsson, J. F., Larsson, S. C., Li, X., Du, Z., & Yuan, S. (2024). Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease. Diabetes, Obesity and Metabolism. Portico. https://doi.org/10.1111/dom.16087
Publication Date
Columbia Affiliation
Wharton, W., Anderson, A., Hayden, K. M., Carmichael, O. T., Clark, J. M., Luchsinger, J. A., Espeland, M., & Yasar, S. (2022). Effect of renin‐angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look AHEAD) trial. Diabetes, Obesity and Metabolism, 24(12), 2443–2453. Portico. https://doi.org/10.1111/dom.14838
Publication Date
Columbia Affiliation
Shah, A., Prasad, M., Mark, V., Holst, J. J., & Laferrère, B. (2022). Glucagon‐like peptide‐1 effect on β‐cell function varies according to diabetes remission status after Roux‐en‐Y gastric bypass. Diabetes, Obesity and Metabolism, 24(11), 2081–2089. Portico. https://doi.org/10.1111/dom.14793
Publication Date
Columbia Affiliation
Lund, S. S., Sattar, N., Salsali, A., Neubacher, D., & Ginsberg, H. N. (2021). Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials. Diabetes, Obesity and Metabolism, 23(12), 2763–2774. Portico. https://doi.org/10.1111/dom.14534
Publication Date
Columbia Affiliation
View